Implementing the Medicare $2 drug list model would have reduced out-of-pocket spending by 63% for Part D beneficiaries in 2021. The model caps cost-sharing at $2 for a 30-day supply of 101 generic ...

Analysis of 2012-2021 commercial claims demonstrates that spending growth was concentrated among the highest spenders and there was increasing subsidy across enrollees through cost-sharing design.

Medications for opioid use disorder (MOUD) are underused in the treatment of people with OUD; insurance-related barriers are a possible driving factor. We used Wisconsin’s all-payer claims database ...

As drug overdose deaths reached record levels in the United States, evidence-based treatments for substance use remained significantly underutilized, a new study found. The vast majority of drug ...